Article
Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.
Hereditas - 2 Jan 2021
Chen Zihao, Liu Guojun, Liu Guoqing, Bolkov Mikhail A, Shinwari Khyber, Tuzankina Irina A, Chereshnev Valery A, Wang Zhifeng
Abstract excerpt
Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment. However, the objective response rates (ORR) are relatively low due to the lack of precise biomarkers to select patients. Herein, the molecular subtype, tumor mutation burden (TMB), and CD8+ T cells were calculated by the gene expression and mutation profiles of MIBC patients. MIBC immunotypes were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.